Unlike classical Nrf2 activators (e.g., DMF, sulforaphane), these PPI inhibitors avoid broad redox reactivity, resulting in lower off-target toxicity, improved pharmacokinetics, and enhanced CNS penetration features that are critical for translational utility in neurodegenerative diseases. This evidence concerns the gene NFE2L2 and neurodegenerative disease.